Cargando…

Diagnostic value of two-time point [(68)Ga]Ga-PSMA-11 PET/CT in the primary staging of untreated prostate cancer

The emerging PET tracer [(68)Ga]Ga-PSMA-11 has been established for staging in prostate cancer (PCa). Aim was to determine the value of early static imaging in two-phase PET/CT. 100 men with newly diagnosed histopathologically confirmed untreated PCa who underwent [(68)Ga]Ga-PSMA-11 PET/CT from Janu...

Descripción completa

Detalles Bibliográficos
Autores principales: Weitzer, Friedrich, Pernthaler, Birgit, Plhak, Elisabeth, Riedl, Regina, Aigner, Reingard Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202919/
https://www.ncbi.nlm.nih.gov/pubmed/37217532
http://dx.doi.org/10.1038/s41598-023-35628-0
_version_ 1785045521599037440
author Weitzer, Friedrich
Pernthaler, Birgit
Plhak, Elisabeth
Riedl, Regina
Aigner, Reingard Maria
author_facet Weitzer, Friedrich
Pernthaler, Birgit
Plhak, Elisabeth
Riedl, Regina
Aigner, Reingard Maria
author_sort Weitzer, Friedrich
collection PubMed
description The emerging PET tracer [(68)Ga]Ga-PSMA-11 has been established for staging in prostate cancer (PCa). Aim was to determine the value of early static imaging in two-phase PET/CT. 100 men with newly diagnosed histopathologically confirmed untreated PCa who underwent [(68)Ga]Ga-PSMA-11 PET/CT from January 2017 to October 2019 were included. The two-phase imaging protocol consisted of an early static scan of the pelvis (6 min p.i.) and a late total-body scan (60 min p.i). Associations of semi-quantitative parameters derived via volumes of interest (VOI) with Gleason grade group and PSA were investigated. In 94/100 patients (94%) the primary tumor was detected in both phases. In 29/100 patients (29%) metastases were detected at a median PSA level of 32.2 ng/ml (0.41–503 ng/ml). In 71/100 patients (71%) without metastasis a median PSA level of 10.1 ng/ml (0.57–103 ng/ml) was observed (p = < 0.001). Primary tumors demonstrated a median standard uptake value maximum (SUVmax) of 8.2 (3.1–45.3) in early phase versus 12.2 (3.1–73.4) in late phase and a median standard uptake value mean (SUVmean) of 4.2 (1.6–24.1) in early phase versus 5.8 (1.6–39.9) in late phase, significantly increasing over time (p = < 0.001). Higher SUVmax and SUVmean were associated with higher Gleason grade group (p = 0.004 and p = 0.003, respectively) and higher PSA levels (p = < 0.001). In 13/100 patients the semi-quantitative parameters including SUVmax were declining in the late phase compared to early phase. Two-phase [(68)Ga]Ga-PSMA-11 PET/CT demonstrates a high detection rate for primary tumor of untreated PCa of 94% and improves diagnostic accuracy. Higher PSA levels and Gleason grade group are associated with higher semi-quantitative parameters in the primary tumor. Early imaging provides additional information in a small sub-group with declining semi-quantitative parameters in the late phase.
format Online
Article
Text
id pubmed-10202919
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102029192023-05-24 Diagnostic value of two-time point [(68)Ga]Ga-PSMA-11 PET/CT in the primary staging of untreated prostate cancer Weitzer, Friedrich Pernthaler, Birgit Plhak, Elisabeth Riedl, Regina Aigner, Reingard Maria Sci Rep Article The emerging PET tracer [(68)Ga]Ga-PSMA-11 has been established for staging in prostate cancer (PCa). Aim was to determine the value of early static imaging in two-phase PET/CT. 100 men with newly diagnosed histopathologically confirmed untreated PCa who underwent [(68)Ga]Ga-PSMA-11 PET/CT from January 2017 to October 2019 were included. The two-phase imaging protocol consisted of an early static scan of the pelvis (6 min p.i.) and a late total-body scan (60 min p.i). Associations of semi-quantitative parameters derived via volumes of interest (VOI) with Gleason grade group and PSA were investigated. In 94/100 patients (94%) the primary tumor was detected in both phases. In 29/100 patients (29%) metastases were detected at a median PSA level of 32.2 ng/ml (0.41–503 ng/ml). In 71/100 patients (71%) without metastasis a median PSA level of 10.1 ng/ml (0.57–103 ng/ml) was observed (p = < 0.001). Primary tumors demonstrated a median standard uptake value maximum (SUVmax) of 8.2 (3.1–45.3) in early phase versus 12.2 (3.1–73.4) in late phase and a median standard uptake value mean (SUVmean) of 4.2 (1.6–24.1) in early phase versus 5.8 (1.6–39.9) in late phase, significantly increasing over time (p = < 0.001). Higher SUVmax and SUVmean were associated with higher Gleason grade group (p = 0.004 and p = 0.003, respectively) and higher PSA levels (p = < 0.001). In 13/100 patients the semi-quantitative parameters including SUVmax were declining in the late phase compared to early phase. Two-phase [(68)Ga]Ga-PSMA-11 PET/CT demonstrates a high detection rate for primary tumor of untreated PCa of 94% and improves diagnostic accuracy. Higher PSA levels and Gleason grade group are associated with higher semi-quantitative parameters in the primary tumor. Early imaging provides additional information in a small sub-group with declining semi-quantitative parameters in the late phase. Nature Publishing Group UK 2023-05-22 /pmc/articles/PMC10202919/ /pubmed/37217532 http://dx.doi.org/10.1038/s41598-023-35628-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Weitzer, Friedrich
Pernthaler, Birgit
Plhak, Elisabeth
Riedl, Regina
Aigner, Reingard Maria
Diagnostic value of two-time point [(68)Ga]Ga-PSMA-11 PET/CT in the primary staging of untreated prostate cancer
title Diagnostic value of two-time point [(68)Ga]Ga-PSMA-11 PET/CT in the primary staging of untreated prostate cancer
title_full Diagnostic value of two-time point [(68)Ga]Ga-PSMA-11 PET/CT in the primary staging of untreated prostate cancer
title_fullStr Diagnostic value of two-time point [(68)Ga]Ga-PSMA-11 PET/CT in the primary staging of untreated prostate cancer
title_full_unstemmed Diagnostic value of two-time point [(68)Ga]Ga-PSMA-11 PET/CT in the primary staging of untreated prostate cancer
title_short Diagnostic value of two-time point [(68)Ga]Ga-PSMA-11 PET/CT in the primary staging of untreated prostate cancer
title_sort diagnostic value of two-time point [(68)ga]ga-psma-11 pet/ct in the primary staging of untreated prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202919/
https://www.ncbi.nlm.nih.gov/pubmed/37217532
http://dx.doi.org/10.1038/s41598-023-35628-0
work_keys_str_mv AT weitzerfriedrich diagnosticvalueoftwotimepoint68gagapsma11petctintheprimarystagingofuntreatedprostatecancer
AT pernthalerbirgit diagnosticvalueoftwotimepoint68gagapsma11petctintheprimarystagingofuntreatedprostatecancer
AT plhakelisabeth diagnosticvalueoftwotimepoint68gagapsma11petctintheprimarystagingofuntreatedprostatecancer
AT riedlregina diagnosticvalueoftwotimepoint68gagapsma11petctintheprimarystagingofuntreatedprostatecancer
AT aignerreingardmaria diagnosticvalueoftwotimepoint68gagapsma11petctintheprimarystagingofuntreatedprostatecancer